Want to see TRIB full AI Analyst Report?
Top Page
Trinity Biotech
(NASDAQ:TRIB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$9.50
▲(12.56% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily weighed down by weak financial performance, including sustained losses, negative equity, rising debt, and ongoing cash burn (despite some free-cash-flow improvement in 2025). Technicals add only modest support with a short-term lift above the 20-day average but a broader downtrend versus longer moving averages, while valuation is difficult to support given negative earnings and no dividend yield data.
Positive Factors
Q1 revenue and margin recovery
The sharp Q1 revenue rebound and improved gross margin indicate stronger demand for HIV and haemoglobin products, while outsourced manufacturing may support better cost efficiency and provide a foundation for more sustainable operating improvement.
Negative Factors
Highly stressed balance sheet
Persistent negative equity and rising debt indicate a fragile capital structure, limiting the company’s ability to absorb setbacks or fund growth internally. Refinancing dependence may increase interest costs, dilution risk and vulnerability to lender conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Q1 revenue and margin recovery
The sharp Q1 revenue rebound and improved gross margin indicate stronger demand for HIV and haemoglobin products, while outsourced manufacturing may support better cost efficiency and provide a foundation for more sustainable operating improvement.
Read all positive factors
Trinity Biotech (TRIB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.24M
Dividend YieldN/A
Average Volume (3M)136.14K
Price to Earnings (P/E)―
Beta (1Y)2.56
Revenue Growth-13.28%
EPS Growth39.65%
CountryUS
Employees287
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-60.60
Shares Outstanding813,132
10 Day Avg. Volume159,092
30 Day Avg. Volume136,139
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.20
Price to Sales (P/S)0.34
P/FCF Ratio-1.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-32.7
Revenue Forecast (FY)$59.50M
Trinity Biotech Business Overview & Revenue Model
Company Description
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Af...
How the Company Makes Money
Trinity Biotech primarily makes money by selling diagnostic products and related consumables used to run clinical tests. Key revenue streams have historically included: (1) Reagents and test kits: recurring sales of assay reagents and test kits (f...
Trinity Biotech Earnings Call Summary
Earnings Call Date:Nov 15, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Sep 03, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.Positive Updates
Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
Negative Updates
Hemoglobin Revenue Decline
Hemoglobin revenues from A1c testing products were lower in Q3 2024 compared to Q3 2023, due to uneven ordering patterns and decreased instrument sales.
Read all updates
Q3-2024 Updates
Positive
Negative
Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
Read all positive updates
Company Guidance
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.Trinity Biotech Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 43.78M | 61.55M | 56.83M | 62.52M | 81.15M |
| Gross Profit | 16.89M | 21.44M | 19.45M | 22.05M | 33.45M |
| EBITDA | -21.38M | -16.91M | -24.10M | -16.71M | 10.59M |
| Net Income | -37.38M | -31.79M | -24.02M | -41.00M | 875.00K |
Balance Sheet | |||||
| Total Assets | 105.17M | 103.29M | 59.44M | 92.10M | 118.89M |
| Cash, Cash Equivalents and Short-Term Investments | 5.14M | 5.17M | 3.69M | 6.58M | 25.91M |
| Total Debt | 137.98M | 100.76M | 67.43M | 72.20M | 99.16M |
| Total Liabilities | 177.15M | 138.47M | 83.38M | 94.28M | 119.21M |
| Stockholders Equity | -71.98M | -35.18M | -23.95M | -2.18M | -319.00K |
Cash Flow | |||||
| Free Cash Flow | -12.15M | -14.26M | -12.36M | -6.90M | 4.55M |
| Operating Cash Flow | -5.93M | -4.19M | -11.56M | -921.00K | 13.24M |
| Investing Cash Flow | -6.22M | -22.97M | 24.76M | -5.98M | -8.69M |
| Financing Cash Flow | 12.05M | 28.81M | -16.04M | -12.32M | -6.02M |
Trinity Biotech Technical Analysis
Negative
8.44
Price Trends
11.31
Negative
15.38
Negative
19.79
Negative
Market Momentum
-0.59
Positive
40.19
Neutral
6.51
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Negative. The current price of 8.44 is below the 20-day moving average (MA) of 11.18, below the 50-day MA of 11.31, and below the 200-day MA of 19.79, indicating a bearish trend. The MACD of -0.59 indicates Positive momentum. The RSI at 40.19 is Neutral, neither overbought nor oversold. The STOCH value of 6.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRIB.
Trinity Biotech Risk Analysis
Trinity Biotech disclosed 1 risk factors in its most recent earnings report. Trinity Biotech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
Trinity Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $51.65M | -44.38 | -8.49% | ― | 28.04% | 43.26% | |
52 Neutral | $13.78M | -0.31 | -71.38% | ― | 10.03% | 91.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.14M | -0.25 | -174.16% | ― | 38.09% | 54.22% | |
42 Neutral | $6.24M | -0.16 | 68.09% | ― | -13.28% | 39.65% | |
41 Neutral | $2.88M | -0.04 | -257.27% | ― | -23.17% | 67.18% |
* Healthcare Sector Average
TRIB
Trinity Biotech
9.68
-34.12
-77.90%
PRPO
Precipio
28.85
13.44
87.22%
BNGO
BioNano Genomics
1.17
-2.92
-71.39%
INBS
Intelligent Bio Solutions
2.36
-13.54
-85.16%
BIAF
bioAffinity Technologies, Inc.
4.87
-104.07
-95.53%
Trinity Biotech Corporate Events
Trinity Biotech Advances Diagnostics Transformation as Nasdaq Compliance Pressure Mounts
Aug 28, 2026
On August 28, 2026, Trinity Biotech reported progress in its diagnostics business, highlighting the appointment of Jordi Romero as Head of Commercial Operations – Europe to strengthen sales execution and accelerate growth in key internationa...
Trinity Biotech’s Trinovium Strikes Liquid Cooling Collaboration with Echelon for AI Data Centers
Aug 17, 2026
On August 17, 2026, Trinity Biotech’s Trinovium subsidiary entered into a strategic collaboration with Echelon Data Centres to develop advanced liquid cooling solutions for AI and high-density computing infrastructure. The partnership combin...
Trinity Biotech Gains $7 Million from Perceptive Advisors and Restores Nasdaq Bid Price Compliance
Aug 14, 2026
On August 14, 2026, Trinity Biotech announced it had secured approximately $7.0 million in additional investment from funds managed by Perceptive Advisors, its largest financial investor and primary lender, via an amendment to its term loan facili...
Trinity Biotech Moves to One-for-Thirty ADS Reverse Split to Meet Nasdaq Bid Price Rules
Jul 22, 2026
On July 22, 2026, Trinity Biotech plc announced plans to change the ratio of its American depositary shares representing Class A ordinary shares from one ADS for twenty shares to one ADS for six hundred shares. For ADS holders, this effectively co...
Trinity Biotech Strikes Strategic CGM+ Drug-Delivery Pact with Latch Medical
Jul 22, 2026
On July 22, 2026, Trinity Biotech announced a strategic collaboration and planned equity investment in Latch Medical to couple its CGM+ wearable biosensor platform with Latch’s hollow microneedle-based Pharma Latch intradermal drug delivery ...
Trinity Biotech Clinical Data Validates CGM+ Advantage in Tackling False Low Glucose Alerts
Jul 2, 2026
On July 2, 2026, Trinity Biotech reported clinical trial results from a pre-pivotal study of its next-generation CGM+ wearable biosensor platform in insulin-dependent people with diabetes. Analysis of about 5,000 hours of wear time showed CGM+ can...
Trinity Biotech’s Trinovium Joins Open Compute Project, Targeting Rapidly Growing AI Data Center Cooling Market
Jun 30, 2026
On June 30, 2026, Trinity Biotech announced that its newly formed Trinovium subsidiary has secured Silver Membership in the Open Compute Project, a key global forum for hyperscale data center and AI infrastructure standards. The move gives Trinovi...
Trinity Biotech Ends Yorkville Standby Equity Line as Financing Strategy Shifts
Jun 29, 2026
On June 29, 2026, Trinity Biotech announced it had formally delivered notice of termination to YA II PN, an affiliate of Yorkville Advisors Global, ending its Standby Equity Purchase Agreement that provided an equity line of credit. The company st...
Trinity Biotech Launches Trinovium Subsidiary to Target AI Data Center Liquid Cooling
Jun 23, 2026
On June 23, 2026, Trinity Biotech announced the launch of Trinovium, a new subsidiary that will apply the company’s healthcare-grade, ultra-high-purity fluid manufacturing and analytical capabilities to liquid cooling solutions for AI and hi...
Trinity Biotech Wins Major TrinScreen HIV Orders and Posts Strong Q1 2026 Turnaround
Jun 18, 2026
On June 16, 2026, Trinity Biotech reported that it had secured new purchase orders for more than 2 million TrinScreen HIV rapid tests, to be delivered in the third quarter of 2026, highlighting renewed global demand for HIV diagnostics after 2025 ...
Trinity Biotech Launches New $4.35 Million ATM Program with Lucid, Ends Craig-Hallum Mandate
Jun 12, 2026
On June 12, 2026, Trinity Biotech plc entered into a new at-the-market equity offering agreement with Lucid Capital Markets, allowing the company to sell up to $4.35 million of American Depositary Shares from time to time. The Lucid arrangement, c...
Trinity Biotech Secures Interest Capitalization and Covenant Waiver From Perceptive
Jun 5, 2026
Trinity Biotech plc disclosed that it has reached an agreement with its lender, Perceptive Credit Holdings III, LP, to capitalize the interest payable for May 2026 under its existing credit agreement, adding that amount to the outstanding principa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.